Src Family Kinase Inhibitor AP23846 Shows Potential in Cancer Therapy

A novel ATP-based Src family kinase inhibitor, AP23846, has been found to exhibit potent anti-cancer properties, particularly in tumor progression and metastasis. According to a study published in Molecular Cancer Therapeutics, AP23846 inhibited angiogenic protein in tumor cells, blocking the production of vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8), two key pro-angiogenic molecules. This discovery suggests that Src family kinase inhibitors may be effective in treating advanced cancer.

Key Takeaways:

• AP23846 is a potent c-Src kinase inhibitor with an IC50 of approximately 0.5 nmol/L in vitro, 10-fold more potent than PP2, the most widely used commercially available Src family kinase inhibitor.
• At concentrations of 1 micromol/L, AP23846 led to complete Src inhibition for 48 hours in cells, with no cytotoxicity observed.
• AP23846 reduced cellular migration, VEGF, and IL-8 in a dose-dependent fashion in pancreatic adenocarcinoma cells grown in vitro.
• AP23846 inhibited downstream angiogenic processes, including the promotion of migration of hepatic endothelial cells and angiogenesis into gel foams implanted s.c. in mice.
• The study suggests that Src inhibitors may be useful as cancer therapeutic agents in more advanced disease.
• AP23846, a lead compound, is a novel and highly potent Src family kinase inhibitor.

Statistics:

• IC50 of AP23846: approximately 0.5 nmol/L in vitro
• AP23846 is 10-fold more potent than PP2, the most widely used commercially available Src family kinase inhibitor
• Concentration of AP23846 for complete Src inhibition: 1 micromol/L
• Duration of Src inhibition: 48 hours
• Reduction in VEGF and IL-8 by AP23846 in a dose-dependent fashion: up to 50% reduction in vitro
• Inhibition of cellular migration by AP23846: up to 30% reduction in vitro

Sources:

• Summy, J.M., et al. (2005). AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes. Mol Cancer Ther, 4(12), 1900-1911.
• American Association for Cancer Research. (Publisher). Molecular Cancer Therapeutics. 615 Chestnut St., 17th Floor, Philadelphia, PA 19106-4404, USA.